Skip to main content
ADAG
NASDAQ Life Sciences

Adagene, City of Hope Launch Phase 1 Muzastotug/Ivonescimab Trial in MSS Colorectal Cancer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.6
Mkt Cap
$107.429M
52W Low
$1.418
52W High
$4.85
52W Position info
13% above low
Off High info
67% below high
Rel. Volume info
3.6× avg
Market data snapshot near publication time

ADAG is trading near its 52-week low of $1.418 (13% above the low) on elevated volume (3.6× avg).

Summary

Adagene and City of Hope opened an investigator-initiated Phase 1 trial testing muzastotug (ADG126) plus ivonescimab in up to 36 patients with advanced MSS colorectal cancer, with chemotherapy combinations planned as later steps.


Key Events · Product Development and Regulatory · ADAG

  • City of Hope Phase 1 Trial Opens

    An investigator-initiated Phase 1 will enroll up to 36 patients with advanced microsatellite stable colorectal cancer to test ivonescimab plus muzastotug (ADG126).

  • No Sponsor Cost to Adagene

    The study is physician-designed and led by City of Hope, so Adagene funds no trial costs while gaining independent data on its lead asset.

  • Chemotherapy Combinations Planned

    After dose optimization, investigators plan to add 5-FU and then irinotecan, aiming at maintenance and first-line metastatic CRC settings.

  • Third PD-1 Bispecific Combination

    Adagene said this is the third clinical program pairing muzastotug or ADG126 with a next-generation PD-1 bispecific.


Analysis · ADAG · Life Sciences

A third-party academic cancer center is opening a Phase 1 trial pairing Adagene's lead asset muzastotug with ivonescimab, an investigational PD-1/VEGF bispecific, in up to 36 patients with advanced microsatellite stable colorectal cancer. Because the study is investigator-initiated, Adagene bears no sponsor cost yet gains independent clinical data in its core MSS CRC indication and a third PD-1-bispecific combination for ADG126. That broadens the case for muzastotug as a combination backbone, but the readout is years away and the trial tests a combination Adagene does not control, so near-term cash flow is unchanged.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADAG was trading at $1.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $107.4M. The 52-week trading range was $1.42 to $4.85. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADAG - Latest Insights

ADAG
Nov 09, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $1.60 info
Change: -$0.400 (-20%) info
Market Cap: $107.429M info
ADAG
Nov 09, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $1.60 info
Change: -$0.400 (-20%) info
Market Cap: $107.429M info
ADAG
Sep 22, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.21
Real-time Price: $1.60 info
Change: -$1.61 (-50%) info
Market Cap: $107.429M info
ADAG
Sep 22, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.21
Real-time Price: $1.60 info
Change: -$1.61 (-50%) info
Market Cap: $107.429M info
ADAG
Aug 12, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $1.60 info
Change: -$2.20 (-58%) info
Market Cap: $107.429M info